week 5

Reflections and foundational ideas

  • Pause-and-think prompts from the lecture: famous neurotransmitters, what triggers neurotransmitter release, what binding does, diseases/drugs affecting neurotransmitters.
  • This lecture introduces what constitutes a neurotransmitter, main classes, and ways to categorize them, with examples.
  • Also covers how excitatory vs inhibitory effects arise on the postsynaptic neuron using receptors, not just the neurotransmitter identity.

What constitutes a neurotransmitter vs a hormone

  • Neurotransmitter definition: a chemical produced by a neuron, released from the presynaptic terminal into the synaptic cleft, and acting locally at a synapse.
  • Hormone definition: produced by an endocrine gland, secreted into the bloodstream, and acting at distant targets; generally slower but longer-lasting.
  • Key point: same molecules can function as neurotransmitters or hormones depending on origin and destination, illustrating overlap between neurotransmitters and hormones.
  • Some classical neurotransmitters have hormone-like properties (e.g., dopamine, serotonin); some hormones can act as neurotransmitters in certain contexts (e.g., progesterone, estrogen).

Seven core properties of a neurotransmitter

  • Synthesized in the presynaptic neuron.
  • Localized to vesicles in the presynaptic neuron.
  • Released from the presynaptic neuron.
  • Rapidly removed from the synaptic cleft by uptake or degradation.
  • Functional classification as excitatory or inhibitory.
  • Has a specific receptor on the presynaptic or postsynaptic membrane; receptors can be ionotropic (ligand-gated ion channels) or metabotropic (G-protein-coupled receptors).
  • Binding elicits a biological response in the postsynaptic cell (or modulates the presynaptic neuron).

Three overlapping classification schemes for neurotransmitters

  • Functional (excitatory vs inhibitory): effect on postsynaptic membrane potential (e.g., depolarization vs hyperpolarization); receptor context determines outcome (e.g., dopamine can be excitatory or inhibitory depending on receptor).
  • Speed (fast vs slow): ionotropic (fast, ligand-gated ion channels) vs metabotropic (slow, G-protein coupled cascades).
  • Chemistry/structure: esters, amino acids, amines, peptides, nitric oxide (gas), and miscellaneous; these classifications hint at synthesis pathways, receptor targets, and where/when signals act.
  • Note: these categories overlap; some transmitters can fall into multiple groups or change roles by context.

Chemical structure categories and their implications

  • Amines (e.g., indolamines, catecholamines): include dopamine, serotonin, histamine; chemistry and synthesis influence receptor targets and signaling speed.
  • Amino acids: include the major fast excitatory transmitter glutamate and inhibitory transmitter glycine; responsible for classic fast synaptic signaling.
  • Cholinergic transmitter: acetylcholine; chemistry linked to rapid neuromuscular transmission and also widely used in CNS circuits.
  • Peptides: can function as neuromodulators, affecting circuit tone rather than only one-to-one synaptic transmission.
  • Nitric oxide (gas): unconventional transmitter with distinct diffusion properties.
  • Miscellaneous chemistry: other transmitters that don’t fit neatly into the above groups.
  • Practical takeaway: chemical structure hints at synthesis routes, speed of action, brain distribution, and whether signaling is fast or modulatory.

Classical excitatory and inhibitory signals; role of receptors

  • Glutamate: the brain’s main excitatory neurotransmitter; major role in learning, memory, and synaptic plasticity.
  • GABA: the brain’s main inhibitory neurotransmitter; acts as a brake on excitation.
  • Importantly, the functional classification (excitatory/inhibitory) depends on the receptor type and downstream effects, not just the transmitter identity.
  • Dopamine often acts as a neuromodulator rather than a simple one-to-one transmitter, illustrating the complexity of receptor context.

Fast vs slow signaling: ionotropic vs metabotropic receptors

  • Fast signaling (ionotropic): neurotransmitter binds directly to ligand-gated ion channels, causing rapid opening/closing of ion channels and immediate changes in membrane potential.
    • Examples: AMPA receptors (glutamate), GABA-A receptors (GABA).
  • Slow signaling (metabotropic): neurotransmitter binds to G-protein coupled receptors, triggering secondary messenger cascades that modulate ion channels and other intracellular targets; can alter receptor expression and synaptic efficacy over longer timescales.
    • Examples: NMDA receptor (also ligand-gated but often discussed in the context of voltage-dependency); dopamine, norepinephrine through metabotropic receptors.
  • Neuromodulators (e.g., dopamine, serotonin, acetylcholine in some contexts) often act through metabotropic receptors to modulate circuit function rather than simply triggering a fast synaptic event.

Glutamate, GABA, and the tripartite synapse

  • Glutamate (major excitatory transmitter): fast signaling via ionotropic receptors (AMPA, NMDA) and metabotropic receptors as well.
  • NMDA receptor specifics:
    • Coincidence detector: requires glutamate binding and a co-agonist (glycine) plus depolarization to relieve Mg^{2+} block for channel opening.
    • AMPA receptors depolarize the membrane to help relieve Mg^{2+} block on NMDA receptors.
    • NMDA receptor involvement is critical for certain forms of plasticity and learning; excessive NMDA activation can lead to excitotoxicity.
  • Glutamate clearance requires a tripartite system involving glial cells:
    • Glutamate is taken up from the synaptic cleft by glia (astrocytes) after release.
    • In glia, it is converted to glutamine and transported back to presynaptic neurons where it is converted back to glutamate for storage and reuse.
    • This astrocyte-mediated process terminates the signal and supplies precursors for new transmitter synthesis.
  • Tripartite synapse concept: the synapse includes presynaptic neuron, postsynaptic neuron, and surrounding glial cells that contribute to neurotransmitter cycling and signaling regulation.

GABA: synthesis, receptors, and termination of signaling

  • GABA is produced from glutamate via the enzyme glutamic acid decarboxylase (GAD).
  • GABA receptors:
    • GABA-A: ionotropic receptor (ligand-gated chloride channel) that hyperpolarizes the postsynaptic cell when activated.
    • GABA-B: metabotropic receptor (G-protein coupled) with slower, modulatory effects.
  • Removal of GABA from the synapse:
    • Primary mechanism: reuptake into neurons via GABA transporters and rapid vesicle recycling.
    • Secondary mechanism: astrocyte uptake with subsequent metabolism and recycling of GABA back to glutamate and glutamine.
  • Pharmacological implications: enhancing GABA activity produces depressant/sedative effects (e.g., benzodiazepines, alcohol, anesthetics, some mushrooms) by increasing inhibition; caffeine can indirectly reduce GABA activity, contributing to wakefulness.

Biogenic monoamines and neuromodulation

  • Monoamines include norepinephrine (noradrenaline) and dopamine, among others; they often act as neuromodulators affecting circuits rather than one-to-one transmissions.
  • Norepinephrine (noradrenaline): primarily excitatory; receptors include multiple metabotropic subtypes; roles in arousal, attention, wakefulness, and fight/flight responses in the periphery.
    • Peripheral effects: increased heart rate, breathing, sweating; decreased digestion during stress/fight-or-flight.
    • Central effects: maintains alertness and wakefulness; imbalance can contribute to autonomic issues or REM sleep disruption.
    • Receptors have tissue-specific effects (e.g., alpha-1, alpha-2, beta subtypes) leading to contraction or relaxation of various smooth muscles depending on tissue.
  • Dopamine: five metabotropic receptors (D1–D5), all GPCRs; two major functional groups:
    • D1-like receptors (D1, D5): typically excitatory effects through Gs coupling increasing cAMP.
    • D2-like receptors (D2, D3, D4): typically inhibitory effects through Gi coupling reducing cAMP.
    • Dopamine acts as a neuromodulator, shaping how responsive a neuron or circuit is to input by altering receptor sensitivity, ion channel activity, and even presynaptic release probability.
  • Dopamine pathways and functions:
    • Reward, motivation, movement control; implicated in addiction, psychiatric disorders.
    • Involvement in many brain circuits; dopamine’s role as a neuromodulator extends beyond single synapses.
  • Synthesis and termination:
    • Tyrosine → L-DOPA → dopamine; dopamine cannot cross the blood-brain barrier, hence central synthesis.
    • Vesicular storage and a dopamine transporter recycle it; monoamine oxidase (MAO) degrades dopamine.
  • Clinical connections:
    • Parkinson’s disease: degeneration of dopaminergic neurons in the substantia nigra; treated with L-DOPA to replenish dopamine levels.
    • ADHD: possible involvement of altered dopamine transporter function leading to lower synaptic dopamine availability.
    • Tourette syndrome: suggested excessive dopamine activity in certain striatal circuits.
  • Cocaine as a dopamine-targeting drug:
    • Cocaine blocks the dopamine transporter, preventing reuptake and termination of dopamine signaling.
    • Results in prolonged dopaminergic activation, especially in mesolimbic reward circuitry (nucleus accumbens, prefrontal cortex), producing intense feelings of reward and reinforcement.
    • Repeated exposure can lead to long-term neuroadaptive changes and adverse effects.

Norepinephrine and brain–body interactions; fight/flight context

  • Norepinephrine’s central role: arousal, attention, wakefulness; peripheral role in fight-or-flight responses.
  • Receptor-specific actions:
    • Alpha-1 receptors: smooth muscle contraction (periphery).
    • Beta receptors: heart muscle contraction and smooth muscle relaxation; varied tissue responses.
  • Clinical implications of imbalance:
    • Autonomic failure (e.g., hypotension, reduced heart rate) can occur with insufficient norepinephrine signaling (seen in Parkinson’s, diabetes, etc.).
    • Chronic excess (sympathetic overactivation) linked to high blood pressure, gastrointestinal problems, impaired immune function, and delayed recovery.
  • Impact on sleep: norepinephrine influences REM sleep; high levels can suppress REM sleep.

Acetylcholine (ACh): a cornerstone neurotransmitter

  • Cholinergic signaling uses acetylcholine; widespread in CNS and at neuromuscular junctions.
  • Primary function: excitation at skeletal muscle neuromuscular junctions leading to contraction. Receptor-dependent effects elsewhere can be excitatory or inhibitory.
  • Receptors:
    • Nicotinic cholinergic receptors (nAChR): ligand-gated ion channels; two main subtypes:
    • Nn (neuronal) subtype: located in autonomic ganglia.
    • Nm (muscle) subtype: located at neuromuscular junction; mediates skeletal muscle contraction.
    • Muscarinic cholinergic receptors (mAChR): metabotropic GPCRs with multiple subtypes; some are excitatory and others inhibitory depending on tissue.
  • Eponym and historical note: receptors named after muscarine (found in Amanita muscaria mushrooms), which helped reveal cholinergic receptor classes.
  • Enzymatic activity: acetylcholine esterase (AChE) breaks ACh into choline and acetyl group, terminating signaling. Relevant for drug/disease contexts because some agents inhibit AChE, prolonging ACh action (e.g., sarin).
  • Disease and dysfunctions:
    • Alzheimer’s disease: memory problems linked to reduced acetylcholine production in hippocampus; cholinergic networks implicated in memory recall.
    • Myasthenia gravis: autoimmune destruction of postsynaptic acetylcholine receptors at the NMJ → reduced skeletal muscle contraction.
    • Lambert-Eaton myasthenic syndrome: autoimmune attack on presynaptic voltage-gated calcium channels, reducing acetylcholine release despite proper receptor presence.
  • Toxicology example: sarin (a nerve agent) inhibits acetylcholinesterase, causing prolonged ACh receptor activation and potentially fatal respiratory failure due to sustained skeletal muscle contraction.

Glutamate in detail; excitatory signaling and excitotoxicity

  • Glutamate: most abundant excitatory neurotransmitter in the brain; essential for learning, memory, and synaptic plasticity.
  • Dietary analogy: monosodium glutamate (MSG) can produce similar signaling, sometimes causing mild symptoms in large amounts.
  • Receptors:
    • Ionotropic: AMPA and NMDA receptors.
    • NMDA receptor specifics: ligand- and voltage-dependent; requires glutamate and glycine as co-agonists; Mg^{2+} block at resting potential that requires depolarization to be relieved.
    • The AMPA receptor near NMDA receptors helps depolarize the postsynaptic membrane to enable NMDA channel opening.
    • Metabotropic glutamate receptors (mGluRs) exist as well but are not the focus here.
  • Glutamate-glutamine cycle:
    • Glutamine (precursor) is imported into presynaptic glutamatergic neuron, converted to glutamate and stored in vesicles.
    • After release, glutamate is cleared by transport into neighboring glial cells, where it is converted back to glutamine and shuttled back to neurons for reuse.
  • Pathophysiology: excitotoxicity—excessive glutamatergic activity can contribute to neuronal injury and death, implicated in stroke, ischemia, and traumatic brain injury.

Glial contribution to neurotransmission

  • Glial cells (astrocytes) actively regulate synaptic transmission, particularly for glutamate clearance and GABA cycling.
  • Tripartite synapse framework emphasizes the active role of glia in shaping synaptic efficacy and termination of signaling.

GABA: inhibitory control and clinical relevance

  • GABA synthesis: from glutamate via glutamate decarboxylase (GAD).
  • Receptors:
    • GABA-A: ionotropic, chloride-permeable channel; fast inhibitory postsynaptic potential.
    • GABA-B: metabotropic GPCR; slower, modulatory inhibition.
  • Termination/clearance:
    • Primary: GABA reuptake into neurons via GABA transporters.
    • Secondary: astrocytic uptake with metabolism back to glutamate and then glutamine.
  • Pharmacology and behavior:
    • Benzodiazepines, alcohol, anesthetics, and some mushrooms increase GABA-A activity, producing depressant/sedative effects.
    • Caffeine can block GABA activity indirectly, contributing to wakefulness.

Dopamine as a neuromodulator; receptor diversity and implications

  • Receptors: D<em>1,D</em>2,D<em>3,D</em>4,D5D<em>1, D</em>2, D<em>3, D</em>4, D_5 (five receptors, all metabotropic).
  • Functional grouping:
    • D<em>1D<em>1-like receptors (e.g., D</em>1,D5D</em>1, D_5): generally excitatory (Gs).
    • D<em>2D<em>2-like receptors (e.g., D</em>2,D<em>3,D</em>4D</em>2, D<em>3, D</em>4): generally inhibitory (Gi).
  • Role in circuits: widely used across brain regions to modulate reward, motivation, movement, cognition.
  • Synthesis and termination:
    • Tyrosine → L-DOPA → dopamine; dopamine can’t cross the blood-brain barrier, hence central synthesis is essential.
    • Dopamine transporter recycles dopamine; monoamine oxidase (MAO) degrades dopamine.
  • Clinical relevance:
    • Parkinson’s disease: degeneration of nigrostriatal dopamine neurons; treated with L-DOPA to replenish dopamine.
    • ADHD: potential dopaminergic system involvement affecting attention and motivation.
    • Tourette syndrome: possible excessive dopamine signaling in striatal circuits.
  • Cocaine mechanism and consequences:
    • Cocaine blocks the dopamine transporter, preventing reuptake and prolonging dopamine signaling.
    • Acute effects: intense euphoria and reward; chronic effects include neuroadaptive changes and risk of long-term harm.

Ketamine: emergence, mechanism, and research context

  • Brief background: synthesized in 1956; FDA approval as analgesic/anesthetic in 1970; has gained attention for rapid, sustained antidepressant effects in PTSD and depression.
  • Pharmacology: ketamine is a noncompetitive NMDA receptor antagonist (block of NMDA receptor activation).
  • Ketamine formulations: racemic mix (equal parts R-ketamine and S-ketamine); increasingly used in single-enantiomer forms with distinct profiles.
  • Mechanistic hypotheses:
    • Drug hypothesis: ketamine blocks NMDA receptors on principal glutamatergic neurons, removing a brake on synaptic activity, increasing BDNF release and AMPA receptor activity; promotes synaptic strengthening and neuroplasticity via downstream PRK B signaling and mTOR involvement.
    • Disinhibition hypothesis: ketamine blocks NMDA receptors on GABAergic interneurons, reducing their inhibitory control over excitatory pyramidal neurons; this disinhibition increases glutamatergic transmission, promoting BDNF release and mTOR signaling, leading to synaptogenesis and neurogenesis.
  • Downstream effects and plasticity:
    • BDNF (brain-derived neurotrophic factor) and mTOR pathways are central to ketamine’s rapid and longer-lasting effects via synaptogenesis and neuroplastic changes.
    • Ketamine has been studied as a potential treatment for PTSD and major depressive disorder due to these rapid neural adaptations.
  • Research and clinical study context (PhD example):
    • Investigates low-dose, oral ketamine for PTSD; explores safety, tolerability, efficacy, and underlying neural changes (MRI, EEG, cognitive tests, blood tests).
    • PTSD symptom measurement example: PTSD Checklist for DSM-5 (PCL-5).
    • Study design elements touched on: recruitment, baseline and follow-up assessments, and outcome measures.
  • Research design considerations and ethics (general guidance from the lecture):
    • Start with a broad question, then narrow with literature and expert input.
    • Define target population, inclusion/exclusion criteria, study duration, recruitment methods, measures to include, and expected results.
    • Experimental arms (e.g., active treatment vs placebo or sham) and blinding strategies (open-label vs blinded); route of administration; contraindications; risks; resource requirements.
    • Determine necessary staffing/equipment; assess feasibility and ethics; anticipate what is not known and consult statisticians for analysis plans.

Linking neurotransmitter biology to real-world implications

  • Disease states and conditions reviewed span neurodegenerative (e.g., Parkinson’s disease), psychiatric (e.g., PTSD, ADHD, Tourette syndrome, anxiety), and autonomic dysfunction conditions.
  • Drugs and toxins illustrate how altering neurotransmitter systems can profoundly affect physiology and behavior:
    • Acetylcholine disruption affects skeletal muscle function and memory.
    • Glutamate and NMDA receptor function are central to learning, plasticity, and excitotoxic risk.
    • GABA modulation underpins sedative and anxiolytic effects; caffeine modulates arousal via indirect effects on GABA signaling.
    • Dopamine’s role in reward pathways explains drug abuse potential and motor disorders.
    • Ketamine represents a novel therapeutic approach by engaging glutamatergic plasticity rather than classic monoaminergic targets.
  • Ethical and practical implications of neuroscience research:
    • Balancing potential therapeutic benefits with risks and side effects.
    • Designing robust clinical trials with appropriate control conditions, blinding, dosing strategies, and follow-up.
    • Considering broader societal impacts of drugs that alter cognition, mood, and behavior.

Quick reference: key receptor-and-function highlights (summary)

  • Acetylcholine:
    • Nicotinic receptors: Nm (neuromuscular) and Nn (neuronal/autonomic); fast, excitatory Na^+ influx at NMJ.
    • Muscarinic receptors: M1–M5; metabotropic; diverse excitatory/inhibitory effects depending on subtype and tissue.
    • AChE: enzyme that terminates signaling; sarin inhibits AChE, causing prolonged receptor activation.
  • Glutamate:
    • AMPA receptors: fast excitatory currents.
    • NMDA receptors: COINCIDENCE DEPENDENT; require glutamate and glycine plus depolarization to relieve Mg^2+ block; involved in synaptic plasticity and excitotoxicity.
    • Tripartite synapse: glial involvement in glutamate cycling and termination.
  • GABA:
    • GABA-A: fast inhibitory ion channel (Cl^- influx).
    • GABA-B: slower, metabotropic inhibition.
  • Dopamine:
    • Receptors: D<em>1,D</em>2,D<em>3,D</em>4,D<em>5D<em>1, D</em>2, D<em>3, D</em>4, D<em>5; D</em>1D</em>1-like (excitatory) and D2D_2-like (inhibitory).
    • Roles in reward, movement, and psychiatric conditions; affected by cocaine via transporter blockade.
  • Norepinephrine:
    • Broad role in arousal, attention, and fight/flight; receptor-specific tissue effects influence cardiovascular and visceral responses.
  • Ketamine:
    • NMDA receptor antagonist; rapid antidepressant effects via BDNF/mTOR and neuroplasticity; supported by two main mechanistic hypotheses (drug vs disinhibition).

End of notes

  • These notes consolidate the major and minor points from the transcript, with explicit examples, mechanisms, and clinical implications. They are organized to support exam preparation and linkage to prior lectures on neural signaling, synaptic transmission, and brain plasticity.